Search

Corvus Pharmaceuticals Inc

Gesloten

15.65 2.89

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

15.14

Max

15.63

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.4M

-14M

EPS

-0.15

Werknemers

37

EBITDA

312K

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+108.31% upside

Dividenden

By Acuity

Volgende Winsten

6 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-199M

1.1B

Vorige openingsprijs

12.76

Vorige sluitingsprijs

15.65

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 jul 2026, 23:56 UTC

Correlated Moves

Costco Wholesale Corp's shares are lower in after-market hours, reflecting a slight decline since Monday's close amid broader market trends.

6 jul 2026, 23:56 UTC

Biogen Inc. shares are higher in after-market trading, reflecting a slight upward movement since Monday's close and settling near the upper end of their one-month range.

6 jul 2026, 23:56 UTC

ETF Constituents

SPDR S&P Regional Banking ETF shows gains in after-market trading, driven by contributions from Citizens Financial Group and East West Bancorp.

6 jul 2026, 23:56 UTC

Correlated Moves
ETF Constituents

Vanguard Information Technology ETF shows little change in after-market trading, with top contributors AMD, Microsoft, and NVIDIA posting slight negative returns.

6 jul 2026, 23:52 UTC

Correlated Moves
Social Media

Lam Research shares decline in after-market trading amid broader market weakness and recent insider selling of $11.70 million by Timothy Archer.

6 jul 2026, 23:52 UTC

Mixed trading in European equity indices as Germany's DAX rises on strong factory orders, while FTSE 100 and CAC 40 dip amid disappointing retail sales and cautious ECB outlook.

6 jul 2026, 23:52 UTC

Asia equity markets rise on tech sector optimism, while U.S. mega-cap stocks gain amid strong dollar and mixed European indices ahead of key economic data releases.

6 jul 2026, 23:52 UTC

Global equity markets show mixed performance as U.S. and Asian indices rise while European stocks decline, amid varied economic data signaling resilience in services and manufacturing sectors.

6 jul 2026, 23:52 UTC

U.S. equity markets remain flat post-holiday, with mega-cap tech stocks rising amid expectations of a Federal Reserve interest rate pause following a weak jobs report.

6 jul 2026, 23:52 UTC

Japan's Household Spending Declines 0.4% YoY in May, Beating Expectations and Signaling Potential Recovery Amid Ongoing Inflation Pressures

6 jul 2026, 23:52 UTC

Japan's Household Spending Surges 3.7% MoM in May, Exceeding Expectations and Indicating Consumer Confidence Recovery

6 jul 2026, 23:52 UTC

China's June 2026 Inflation Rate Release Expected at 1.1% Amid Cautious Market Sentiment and Global Economic Influences

6 jul 2026, 23:52 UTC

China's Producer Prices Expected to Rise 4.2% YoY Amid Inflationary Pressures and Strong Manufacturing Sentiment Ahead of July 9 Release

6 jul 2026, 23:52 UTC

Initial Jobless Claims Expected at 220,000 Amid Rising Concerns Over Labor Demand and Economic Outlook

6 jul 2026, 23:52 UTC

China's Inflation Rate Expected to Decrease Slightly by 0.002% in June Amid Global Economic Caution

6 jul 2026, 23:52 UTC

Canada's Ivey PMI forecasted to rise to 59.1 amid recent economic contraction signals and geopolitical uncertainties impacting business confidence.

6 jul 2026, 23:51 UTC

ETF Constituents
Macro News

Geopolitical tensions are driving modest gains for the Energy Select Sector SPDR Fund after-market hours, supported by positive contributions from Exxon Mobil and Chevron.

6 jul 2026, 23:51 UTC

Kraft Heinz Co. shares are lower in after-market trading, reflecting routine movement amid a slight decline in U.S. services PMI and weaker job additions.

6 jul 2026, 23:51 UTC

Fiserv Inc shares are higher in after-market trading, moving near the upper end of their one-month trading range. No specific news was identified for this increase.

6 jul 2026, 23:51 UTC

Correlated Moves

Applied Materials shares are lower in after-market trading, continuing a trend of four consecutive sessions of losses amid broader market weakness and macroeconomic concerns.

6 jul 2026, 23:46 UTC

Correlated Moves
ETF Constituents

Vanguard FTSE Europe ETF traded near unchanged levels in after-market hours, influenced by slight declines in top holdings SAP and BP.

6 jul 2026, 23:46 UTC

Shares of Workday Inc. are lower in after-market trading. The U.S. services PMI fell to 54.0, indicating a slight slowdown in sector expansion.

6 jul 2026, 23:46 UTC

Correlated Moves

U.S. services PMI fell to 54.0 in June, matching expectations. The Dow Jones Index is trading roughly flat amid cautious sentiment on Fed interest rates.

6 jul 2026, 23:46 UTC

Intuitive Surgical shares are higher in after-market trading, continuing an upward trend from the previous three sessions. No specific news was identified for the move.

6 jul 2026, 23:46 UTC

United States Oil Fund LP is trading higher in after-market hours, reflecting a recovery from earlier fluctuations amid mixed global equity performance.

6 jul 2026, 23:41 UTC

Verisk Analytics Inc shares declined during after-market hours, despite a broader market context showing continued expansion in the services sector. No specific news was identified.

6 jul 2026, 23:41 UTC

Correlated Moves

Vanguard Total International Bond ETF rises in after-market trading, reflecting positive bond market sentiment and stability near its one-month trading range.

6 jul 2026, 23:41 UTC

Cognizant Technology Solutions shares are higher in after-market trading, amid broader market assessment of U.S. Services PMI and last week's nonfarm payrolls report.

6 jul 2026, 23:41 UTC

Correlated Moves
Social Media
News

Micron Technology shares are lower in after-market trading, reflecting broader market pressures and concerns over a potential memory oversupply by 2028.

6 jul 2026, 23:41 UTC

ETF Constituents

iShares MSCI Brazil ETF gains in after-market trading, supported by positive sentiment in global equity markets and contributions from PBR.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

108.31% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD  108.31%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat